Some real-world evidence suggests that GLP-1 receptor agonists may offer enhanced protection against stroke and MACE in populations without established CVD [8], but recent analyses reveal that SGLT2 inhibitors and GLP-1 receptor agonists provide comparable protection against stroke [9,10] and myocardial infarction [11]. This evidence concerns the gene SLC5A2 and Stroke.